1 company and 4 research reports found for "Alchemia"
Alchemia is an ASX-listed drug development company with a late stage oncology pipeline and generic f...
No sector reports have been found.
AlchemiaPharmaceutical & healthcare | 03/10/2014
Phase III study results due in October with Alchemia’s HA-Irinotecan in metastatic colorectal cancer represent a defining moment in the company&...
AlchemiaPharmaceutical & healthcare | 25/02/2014
Alchemia is approaching the defining moment in its history, with the top-line data from the pivotal Phase III study of HA-Irinotecan in metastatic col...
AlchemiaPharmaceutical & healthcare | 07/06/2013
Merck Serono’s collaboration on a Phase II trial of HA-Irinotecan in combination with Erbitux (cetuximab) bodes well for validation of Alchemia&...